Equity Overview
Price & Market Data
Price: $7.19
Daily Change: -$0.41 / 5.70%
Daily Range: $6.12 - $9.17
Market Cap: $338,031,133
Daily Volume: 663,835
Performance Metrics
1 Week: 15.16%
1 Month: 152.3%
3 Months: -84.13%
6 Months: -84.13%
1 Year: -84.13%
YTD: -84.13%
Company Details
Employees: 11
Sector: Commercial services
Industry: Miscellaneous commercial services
Country: United States
Details
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.